TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Disease Characteristics:~1. Patient previously diagnosed with multiple myeloma; Durie-Salmon Stage I, II, or III based on standard criteria~2. Progressive disease. For non-secretory multiple myeloma, progressive disease is defined as bone marrow biopsy with \> 25% increase in plasma cells or an absolute increase of at least 10% over prior known level. Alternatively, development of new or worsening of existing lytic bone lesions or soft tissue plasmacytomas, or hypercalcemia (serum calcium \>11.5 mg/dL), or relapse from complete response.~Patient Characteristics:~1. 18 yrs or older~2. Patient has given voluntary written informed consent.~3. Unless post-menopausal or surgically sterilized, a female must be willing to use an acceptable method of birth control~4. Male patient must agree to use an acceptable method for contraception for the duration of the study.~5. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.~6. Life expectancy is at least 3 months.~7. • Absolute Neutrophil Count (ANC) over 1,000/ul without the use of colony stimulating factors~   * Platelets over 50,000/ul without transfusion support 7 days~  * Bilirubin 2.0 mg/dl or less~  * aspartate aminotransferase (AST) 4 times or less upper limit normal Prior Therapy for Multiple Myeloma: Patients must have had at least 2 prior therapeutic regimens~Exclusion Criteria:~* Pregnant or breast feeding~* History of allergic reaction to compounds containing boron or mannitol.~* Active uncontrolled viral (including HIV), bacterial, or fungal infection.~* Grade III or IV toxicity due to previous anti-neoplastic therapy~* More than Grade 2 motor or sensory neuropathy~* Myocardial infarction within 6 months of enrollment or New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled arrhythmias, or electrocardiographic evidence of acute ischemia.~* For any patients whose lifetime cumulative doxorubicin dose exceeds 400mg/m2, patients with left ventricular ejection fraction (LVEF) less than 35% by multigated acquisition (MUGA) .~* Concurrent administration of liposomal doxorubicin, melphalan, and bortezomib (single or two drug combinations of these are permissible)~* Less than 3 weeks since most recent chemotherapy or concurrent chemotherapy~* Use of corticosteroids (mroe than 10 mg prednisone/day or equivalent)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Doxil® + Melphalan + Velcade (DMV) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: JALYN for Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Men will be eligible for the study if:~1. age at least 45 years~2. report symptoms of discomfort or pain in the pelvic region during at least 3 of the previous 6 months~3. total score of at least 12 (out of 43) points on the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) at both a screening and randomization visit~4. IPSS score of at least 8 points 5 tenderness on light palpation of the prostate~6. prostate size estimated to be at least 30cc on digital rectal examination~Exclusion Criteria:~Participants are excluded if~1. prior treatment with dutasteride or finasteride. Alpha blocker therapy within 3 months of randomization.~2. documented urinary tract infection (\>105 colony forming units per ml of a recognized uropathogen)~3. history of renal failure (or calculated creatinine clearance of \< 60 ml/min)~4. symptomatic genital herpes in the last 3 months.~5. unilateral orchalgia without pelvic symptoms~6. a history of active urogenital cancer~7. active urethral stricture.~8. surgery of the lower urinary tract (not including simple diagnostic cystoscopy) in the previous 6 months (including TURP, bladder neck incision, bladder tumor resection, urethrotomy).~9. History of alcohol abuse~10. neurologic disease affecting voiding or the bladder~11. Psychiatric condition that would make it difficult (in opinion of investigator) for patient to participate in the study~12. Other acute or chronic medical condition that would make it difficult (in opinion of investigator) for patient to participate in the study

- Gender: MALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Jaylyn (Type: EXPERIMENTAL): Jalyn: dutasteride 0.5 mg/day and tamsulosin 0.4 mg/day combination tablet
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Digital Cognitive Remote Training in Alzheimer's Disease (MA-EIAD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 60 years old or more~* native French speaker~* Diagnosis of Alzheimer's disease according DMS-V criteria~* early to moderate stage of the disease (MMSE \> 15)~* psychotropic drug treatment without change for three months at least~* signed informed consent~* being affiliated to a social security~Exclusion Criteria:~* not corrected visual or auditory deficit~* motor deficits preventing experimental tests execution~* ongoing participation in cognitive training or stimulation for more than three months~* not having a computer at the place of residence~* refusal of participation~* being under guardianship

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control group (Type: ACTIVE_COMPARATOR): None
- Experimental group 1 (Type: EXPERIMENTAL): Moderate frequency cognitive distance training
- Experimental group 2 (Type: EXPERIMENTAL): High frequency cognitive distance training

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Diagnosis of PNH.~2. Male or female, ≥ 18 years of age~Eligibility Criteria:~Eligibility Criteria Specific for Group 1:~1. PNH Patients who have no history of treatment with any complement inhibitor at any dose.~2. PNH Type III erythrocyte or granulocyte clone size ≥10%~3. Absolute reticulocyte count ≥100×10\^9/liter \[L\].~4. Anemia (Hgb \<10.5 grams/deciliter \[g/dL\]).~5. LDH ≥1.5× upper limit of normal.~6. Platelet count ≥30,000/microliter (µL)~7. Absolute neutrophil count (ANC) ≥750/ µL.~Eligibility Criteria Specific for Group 2:~1. Stable background regimen of at least 24 weeks for eculizumab without change in dose or interval for at least the past 8 weeks~2. Anemia (Hgb \<10 g/dL)~3. Absolute reticulocyte count ≥100×10\^9/L~4. Platelet count ≥30,000/µL~5. Absolute neurophil count (ANC) ≥750/ µL~Eligibility Criteria Specific for Group 3:~1. Patient received danicopan during Study ACH471-103~Key Exclusion Criteria:~1. History of a major organ transplant or hematopoietic stem cell/marrow transplant .~2. Known aplastic anemia or other bone marrow failure that requires HSCT, or if these patients are on immunosuppressive agents for less than 24 weeks.~3. Known underlying bleeding disorders or any other conditions leading to anemia not primarily associated with PNH.~4. Estimated glomerular filtration rate \<30 milliliters/minute/1.73 meters squared and/or are on dialysis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open-label ALXN2050 Monotherapy (Type: EXPERIMENTAL): Experimental: Open-label ALXN2050 Monotherapy ALXN2050 orally administered~Group 1: Patients with PNH who are treatment naïve~Group 2: Patient with PNH who have received complement component 5 (C5) inhibition with eculizumab for at least 6 months, who continue to experience anemia and reticulocytes above the upper limit of normal (ULN)~Group 3: Patients with PNH who have received danicopan monotherapy during study ACH471-103

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of the QLT Proprietary Olopatadine-PPDS in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of allergic conjunctivitis to ragweed for at least one year~* Positive skin prick test to ragweed pollen within 12 months prior to visit 1~* BCVA of at leat 20/400~Exclusion Criteria:~* Structural lid abnormalities (ectropion, entropion)~* Active lid disease ( ie moderate or severe blepharitis, meibomianitis) that requires medical treatment~* Presence of follicular conjunctivitis, anterior uveitis or preauricular lymphadenopathy~* History of ophthalmic abnormality, including a history of dry eye~* Perennial allergic rhinoconjunctivitis having significant allergy to animal dander that cannot be avoided during the study period~* History of chronic bacterial or viral ocular infection, such as herpes keratitis, and/or presence of active bacterial or viral ocular infection~* presence of mucous discharge, excess lacrimation or burning as a symptoms of ocular disease~* Currently on any chronic ocular topical medications~* Use of topical or systemic ocular medications during the study period~* History of complications, adverse events, trauma or disease in the nasolacrimal area~* History of symptomatic epiphoria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lower Puncta Delivery (Type: EXPERIMENTAL): None
- Double Puncta Delivery (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Prehabilitation Exercise Plus Perioperative Optimization of Senior Health

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 60 and above~* Able to speak English.~* seen, scheduled to be seen, or eligible to be seen in Preoperative Optimization of Senior Health (POSH) clinic prior to surgery~* scheduled for general, gynecologic or urologic surgery under the Enhanced Recovery After Surgery (ERAS) protocol, or eligible for ERAS protocol~* Lives within a \~1 hr drive of Duke~* Sedentary (not currently following physical activity guidelines)~* Ambulatory (assistive devices ok)~* Able to give informed consent~* Willing to perform prescribed exercises~Exclusion Criteria:~* Inmate of a correctional facility (i.e. prisoners).~* Documented or suspected family or personal history of malignant hyperthermia.~* Allergy or other contraindication to receiving isoflurane~* Receiving systemic chemotherapy after the first cognitive testing session and before the 6 wk follow up cognitive testing sessions.~* Major head trauma that occurs after the first cognitive testing session and before the 6 wk follow up cognitive testing sessions.~* Anginal symptoms, known coronary artery disease (CAD), or high cardiovascular risk per American College of Cardiology (ACC)/ American Heart Association (AHA) guidelines~* Taking anticoagulants that would preclude lumbar puncture per the American Society of Regional Anesthesia guidelines.~* Diagnosed history of dementia.~* Inability to ambulate independently.~* Otherwise not appropriate for study participation in the judgement of the Principal Investigator, such as (but not limited to) because the patient does not have the cardiopulmonary capacity to complete the exercise regimen.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Exercise Intervention (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Accuracy of Pulse Pressure Variations Measured by a Non Invasive Digital Device to Predict Fluid Responsiveness

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients of the intensive care units of the Lille university-hospital.~* Age greater than or equal to 18.~* Patient insured~* Mechanical ventilation without spontaneous respiratory cycles~* Regular cardiac rhythm~* Prescription by the physician in charge of the patients of a 500 mL volume expansion in less than 30 minutes.~* Patients with sepsis with at least one sign of acute circulatory failure:~  * Tachycardia with heart rate\> 100/min~ * systolic blood pressure \<90mmHg or a decrease \>40mmHg in previously hypertense patient~ * Oliguria \<0.5ml/kg/hour for at least one hour~ * skin mottling~Exclusion Criteria:~* high-grade aortic insufficiency~* transthoracic echogenicity unsuitable for measuring the stroke volume by echo-Doppler~* Spontaneous breathing~* clinical or ultrasonographic evidence of pulmonary edema due to heart failure~* pregnancy~* abdominal compartment syndrome~* Irregular cardiac rhythm

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pulse pressure variations (Type: EXPERIMENTAL): Pulse pressure variations, stroke volume, systemic arterial pressure, heart rate, and respiratory rate are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Pulse pressure variations are obtained by noninvasive (ΔPPCNAP) and invasive (ΔPPART) devices.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cardiox Shunt Detection Technology Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Eighteen (18) years of age or older~* Informed consent documentation understood and signed~* Planned or completed TEE study within the last 12 months~Exclusion Criteria:~* Subjects with a known allergy or sensitivity to Indocyanine Green Dye (ICG) or to Iodide Contrast Dye or Iodides~* Pregnant women or nursing mothers~* Subject unable or unwilling to understand and sign the informed consent~* Subject scheduled for radioactive iodine uptake test (Thyroid test) within 7 days of post screening~* Subjects that have poor renal function such as subjects on dialysis, subjects with a recent history of creatinine \> 2.0 or subjects currently being followed by a nephrologist

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TCD/Cardiox FDS/TEE testing (Type: EXPERIMENTAL): All patients enrolled will be evaluated with TCD and Cardiox FDS and TEE for the presence of RTLS.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Allograft Fibrosis Following Pediatric Cardiac Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Children who underwent heart transplantation prior to age 18~* Followed up at Children's Healthcare of Atlanta~Exclusion Criteria:~* Children without a transplanted heart~* Follow-up not at children's Healthcare of Atlanta

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Weekly Topotecan With Docetaxel in Recurrent Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Recurred greater than 90 days after initial treatment~* At least 1 measurable lesion~* Only 1 prior chemotherapy~* Must be over 18 years of age~* ECOG performance status of 0 - 2~* Adequate hematologic, renal, and hepatic function~Exclusion Criteria:~* No prior use of topotecan, docetaxel, or irinotecan~* No symptomatic brain metastases~* History of cardiac arrhythmias, congestive heart failure, stroke, or embolic events~* No prior investigational agents within 1 month prior~* Lung cancer of mixed histology~* Known uncontrolled seizure disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: OTHER): Weekly intravenous topotecan with intravenous docetaxel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patients with refractory symptomatic heart failure (NYHA Class IV, or Stage D) due to dilated, non-ischemic cardiomyopathy who meet the following criteria:~* Severe clinical heart failure with associated haemodynamic compromise resistant to intensive medical therapy and requiring LVAD implantation~* Duration of heart failure symptoms to be ≥ 12 months prior to LVAD implant~* Documentation of LVEF ≤ 40% at least 1 year prior to LVAD implantation~* LVEF ≤ 30% and cardiomegaly at the time of LVAD implantation as documented by radionuclide or contrast ventriculography or by echocardiography~* Nonischemic etiology confirmed by coronary angiography within two years of enrollment~* Listed for heart transplantation or plan to list for heart transplantation pending successful LVAD implantation in one of the participating centers, as per usual transplant listing policy at each participating center~* \>= 18 years of age~* Body surface area \>= 1.5 m2~* Have an implantable defibrillator in place or a commitment to implant an ICD prior to hospital discharge~* Have undergone insertion within prior 2 weeks or will be inserted with a Heartmate XVE LVAD with use of antimicrobial prophylaxis and drive line restraining belt~Exclusion Criteria:~* Not a heart transplant candidate~* Evidence of active acute myocarditis~* Pulmonary Vascular Resistance \> 6 Wood Units~* History of previous CVA resulting in significant fixed motor deficit limiting ability to perform exercise testing~* Previous prosthetic replacement of aortic and/or mitral valve(s)~* Hypertrophic obstructive cardiomyopathy~* LVIDD \< 5 cm by surface echocardiogram (restrictive cardiomyopathy)~* Irreversible multi-organ failure~* Underlying bleeding disorder, or platelet count \< 75,000, INR \> 2.5 (without Coumadin), or Hgb \< 8.0.~* Pregnant or lactating women or unwilling to utilize two reliable methods of birth control for women of childbearing age~* Receipt of other investigational drug therapy during LVAD support

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LVAD and Clenbuterol (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Systemic Inflammation and Obstructive Sleep Apnea Syndrome: Effect of Atorvastatin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women \> 18 years old~* Subjects diagnosed with OSAS (apnea/hypopnea index = AHI \> 30/h)~* Subjects with clinical ATH from grade I or II controlled with mono-therapy(140\<SAP\<180 mmHg and 90\<DAP\<110 mmHg)~Exclusion Criteria:~* Patients with a history of prior stroke or coronary ischemic disease~* Chronic respiratory disease (PaO2 \< 60 mmHg and/or PaCO2 \> 45 mmHg)~* Lung disease~* Hypothyroidism~* Statin treatment~* Antihypertensive treatment with more than one drug~* Pregnant or lactating women~* Alcohol consumption \> 3 units/day~* Treatment by itraconazole, ketoconazole, antiprotease, fibrates, antivitamin K, diltiazem, verapamil, erythromycin, clarithromycin, cyclosporin.~* Hypersensitivity to one of the drug compounds~* Patients with modified concomitant treatments during the 3 months before inclusion~* Potentially dangerous sleepiness~* Jobs at risk

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Stat/CPAP (Type: PLACEBO_COMPARATOR): Atorvastatin and CPAP treatments
- Stat/sham CPAP (Type: PLACEBO_COMPARATOR): Atorvastatin and sham CPAP treatments
- Placebo/CPAP (Type: SHAM_COMPARATOR): Placebo and CPAP treatments
- Placebo/sham CPAP (Type: ACTIVE_COMPARATOR): Placebo and sham CPAP treatments

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy